The stock of Atara Biotherapeutics Inc (NASDAQ:ATRA) is a huge mover today! About 133,922 shares traded hands. Atara Biotherapeutics Inc (NASDAQ:ATRA) has declined 23.56% since April 5, 2016 and is downtrending. It has underperformed by 25.52% the S&P500.
The move comes after 5 months positive chart setup for the $488.13M company. It was reported on Nov, 7 by Barchart.com. We have $27.06 PT which if reached, will make NASDAQ:ATRA worth $317.28M more.
Atara Biotherapeutics Inc (NASDAQ:ATRA) Ratings Coverage
Out of 6 analysts covering Atara Biotherapeutics (NASDAQ:ATRA), 4 rate it a “Buy”, 2 “Sell”, while 0 “Hold”. This means 67% are positive. Atara Biotherapeutics has been the topic of 13 analyst reports since September 9, 2015 according to StockzIntelligence Inc. On Tuesday, December 15 the stock rating was downgraded by Citigroup to “Sell”. As per Tuesday, December 15, the company rating was maintained by JMP Securities. The stock of Atara Biotherapeutics Inc (NASDAQ:ATRA) has “Buy” rating given on Monday, October 24 by Jefferies. The stock has “Market Outperform” rating given by JMP Securities on Wednesday, March 9. Citigroup maintained Atara Biotherapeutics Inc (NASDAQ:ATRA) rating on Friday, August 19. Citigroup has “Sell” rating and $8 price target. JMP Securities initiated the stock with “Mkt Perform” rating in Friday, September 25 report. Goldman Sachs initiated it with “Neutral” rating and $38 target price in Wednesday, November 18 report. The stock of Atara Biotherapeutics Inc (NASDAQ:ATRA) earned “Buy” rating by Canaccord Genuity on Wednesday, September 9. The firm has “Sell” rating given on Thursday, September 15 by Goldman Sachs. Citigroup maintained it with “Sell” rating and $8 target price in Monday, August 22 report.
According to Zacks Investment Research, “Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. The company’s lead programs are focused on myostatin and activin, members of the TGF-beta family of proteins that have demonstrated the potential to have therapeutic benefit in a number of clinical indications. Its lead product candidate is PINTA 745, which is in a Phase II clinical trial for the treatment of protein-energy wasting in end-stage renal disease patients. Atara Biotherapeutics, Inc. is headquartered in Brisbane, California.”
Insitutional Activity: The institutional sentiment increased to 3.36 in 2016 Q2. Its up 2.20, from 1.16 in 2016Q1. The ratio increased, as 6 funds sold all Atara Biotherapeutics Inc shares owned while 8 reduced positions. 7 funds bought stakes while 40 increased positions. They now own 43.46 million shares or 112.65% more from 20.44 million shares in 2016Q1.
Moreover, State Street has 0% invested in Atara Biotherapeutics Inc (NASDAQ:ATRA) for 355,001 shares. Manufacturers Life The accumulated 16,420 shares or 0% of the stock. Schwab Charles Management holds 66,295 shares or 0% of its portfolio. Legal General Group Public Ltd Com holds 0% or 3,583 shares in its portfolio. Deutsche Natl Bank Ag last reported 9,779 shares in the company. Ladenburg Thalmann has 22 shares for 0% of their US portfolio. Northern Trust, a Illinois-based fund reported 240,735 shares. Arrowpoint Asset Management Lc last reported 0.57% of its portfolio in the stock. Teacher Retirement Sys Of Texas accumulated 0% or 2,391 shares. Tiaa Cref Invest Lc holds 0% of its portfolio in Atara Biotherapeutics Inc (NASDAQ:ATRA) for 71,630 shares. Voya Investment Mgmt Lc accumulated 10,162 shares or 0% of the stock. Retail Bank Of New York Mellon holds 0% or 99,629 shares in its portfolio. Cormorant Asset Management Limited Liability Company has 186,460 shares for 0.6% of their US portfolio. Eagle Asset Management Inc, a Florida-based fund reported 972,592 shares. Ubs Asset Mngmt Americas holds 1.15 million shares or 0.03% of its portfolio.
Insider Transactions: Since May 16, 2016, the stock had 0 insider purchases, and 17 selling transactions for $2.07 million net activity. 4,800 shares were sold by Ciechanover Isaac E., worth $76,608 on Thursday, October 13. 5,000 shares with value of $87,325 were sold by MCGRATH JOHN on Tuesday, October 11. On Monday, May 16 the insider Soffer Gad sold $86,344. On Monday, May 16 the insider Gallagher Carol Giltner sold $18,897. Shares for $24,990 were sold by Haqq Christopher. Another trade for 4,153 shares valued at $62,918 was sold by Clark Mitchall G..
More recent Atara Biotherapeutics Inc (NASDAQ:ATRA) news were published by: Marketwatch.com which released: “Plus the latest data from Realtor.com on 21 home markets across the US” on October 17, 2014. Also Fool.com published the news titled: “Why Atara Biotherapeutics Inc. Shares Are Getting Mauled Today” on December 14, 2015. Quotes.Wsj.com‘s news article titled: “News Atara Biotherapeutics Inc.ATRA” with publication date: July 19, 2014 was also an interesting one.
ATRA Company Profile
Atara Biotherapeutics, Inc., incorporated on August 22, 2012, is a clinical-stage biopharmaceutical company. The Firm is focused on developing therapies for patients with severe and life-threatening diseases. The Company’s segment is the business of developing and commercializing therapeutics. The Firm has approximately two groups of product candidates, such as allogeneic or third-party derived antigen-specific T-cells, and molecularly targeted biologics. The Company’s T-cell product candidates arise from a platform technology designed to produce off-the-shelf, partially human leukocyte antigen (HLA) matched cellular therapeutics utilizing cytotoxic T lymphocytes (CTLs). The Company’s T-cell product candidates target viral or cancer-specific antigens, and are designed to harness the body’s immune system to counteract specific viral infections and cancers. The Company’s T-cell product candidates include Epstein Barr Virus (EBV)-CTL, which is in Phase II clinical trials for malignancies associated with EBV, including EBV-associated post-transplant lymphoproliferative disorders (EBV-PTLD); cytomegalovirus (CMV)-CTL, which is in Phase II clinical trials for CMV, and Wilms Tumor 1 (WT1)-CTL, which targets cancers expressing the antigen WT1 and is in Phase I clinical trials.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.